OCUL — OCULAR THERAPEUTIX, INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1393434 ·
Last close
$6.02
Market Cap
$1.32B
52W High
$16.44
52W Low
$5.80
ADV30
2,990,383
Next earnings
2027-02-04
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 12,874,000 11,419,000 -97,858,000 -94,782,000 605,647,000 530,612,000 164,698,000
Jun 2026 13,475,000 11,464,000 -82,109,000 -78,763,000 671,317,000 598,641,000 151,276,000
Mar 2026 10,785,000 9,456,000 -93,340,000 -88,612,000 732,529,000 666,699,000 150,955,000
Dec 2025 13,250,000 11,656,000 -69,760,000 -64,654,000 808,057,000 737,060,000 153,747,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-253,137,000
Investing CF
$-13,898,000
Financing CF
$452,875,000
CapEx
$-13,898,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.46
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,419,180,000
Inventory
$4,260,000
Receivables
$31,388,000
ST Investments
—
EBIT TTM
$-315,596,000
Pretax Income TTM
$-326,811,000
Interest Exp TTM
$11,215,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$50,384,000
EBITDA
$-336,256,000
Free Cash Flow
$-159,983,872
Enterprise Value
$915,742,848
Total Cash
$530,612,000
Total Debt
$80,013,000
Shares Out
220,022,840
Trailing EPS
$-1.44
Book Value
$2.00
ROE
-93.5%
ROA
-42.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 51,951,000 -270,017,000 -265,939,000 808,057,000 153,747,000 654,310,000 -204,883,000
Dec 2024 63,723,000 -171,781,000 -193,506,000 457,935,000 142,591,000 315,344,000 -134,677,000
Dec 2023 58,443,000 -82,382,000 -80,736,000 252,060,000 160,929,000 91,131,000 -70,234,000
Dec 2022 51,494,000 -78,654,000 -71,038,000 149,289,000 113,910,000 35,379,000 -59,603,000

TTM Snapshot

Revenues TTM
$52,054,000
NetIncome TTM
$-301,447,000
OpCashFlow TTM
—
Assets (Latest)
$671,317,000
Forward EPS
$-1.59

Max Pain — expiry 2026-12-18

max pain strike: $8.00 · spot: $5.94 · call oi: 5,549 · put oi: 871
Expected Move to 2026-12-18: ±$0.64 (10.77%) — implied range $5.30 – $6.58 · ATM straddle on $6.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MNKD MANNKIND CORP $1.31B $4.07 —
LBRX LB PHARMACEUTICALS INC $1.30B $40.30 —
GPCR Structure Therapeutics Inc. $1.30B $18.17 —
INVA Innoviva, Inc. $1.30B $18.30 —
TYRA Tyra Biosciences, Inc. $1.35B $19.57 —

News headlines (Yahoo Finance, 1h cache)

Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists
2026-11-12 04:30 · Yahoo
How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success
2026-11-12 03:14 · Yahoo
Ocular Therapeutix (OCUL) reports earnings tomorrow: what to expect
2026-11-10 16:21 · Yahoo
Ocular Therapeutix Inc (OCUL) Q3 2026 Earnings Call Highlights: Landmark Phase 3 Wins, NDA on ...
2026-11-10 01:02 · Yahoo
Ocular Therapeutix, Inc. Q3 2026 Earnings Call Summary
2026-11-09 22:10 · Yahoo
Ocular Tx (OCUL) Q3 2026 Earnings Call Transcript
2026-11-09 19:14 · Yahoo
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call
2026-11-09 17:15 · Yahoo
Ocular Therapeutix falls on third quarter earnings miss
2026-11-09 15:39 · Yahoo
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
2026-11-09 12:40 · Yahoo
Ocular Therapeutix: Q3 Earnings Snapshot
2026-11-09 12:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.